Journal
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
Volume 288, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.resp.2021.103645
Keywords
COVID-19; Lung infections; SARS-Cov-2; ARDS
Categories
Ask authors/readers for more resources
Studies show that exogenous pulmonary surfactant has clinical efficacy in treating inflammatory lung diseases, particularly ARDS. COVID-19 interferes with the production and secretion of pulmonary surfactant, leading to increased surface tension in alveoli. Therefore, the use of pulmonary surfactant in COVID-19-associated ARDS patients can be beneficial, especially when applied early in treatment strategies against pulmonary failure.
Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an increase in surface tension, which in turn can lead to alveolar collapse. The use of the pulmonary surfactant seems to be promising as an additional therapy for the treatment of ARDS. COVID-19 causes lung damage and ARDS, so beneficial effects of surfactant therapy in COVID-19-associated ARDS patients are conceivable, especially when applied early in the treatment strategy against pulmonary failure. Because of the robust anti-inflammatory and lung protective efficacy and the current urgent need for lung-supportive therapy, the exogenous pulmonary surfactant could be a valid supportive treatment of COVID-19 pneumonia patients in intensive care units in addition to the current standard of ARDS treatment
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available